Ixazomib - Takeda Oncology
Alternative Names: Ixazomib citrate; MLN-2238; MLN-9708; NINLAROLatest Information Update: 16 Aug 2024
At a glance
- Originator Millennium Pharmaceuticals; University of California, San Diego
- Developer Celgene Corporation; Helsinki University Central Hospital; HOVON Foundation; Massachusetts General Hospital; National Cancer Institute (USA); Northside Hospital; Northwestern University; Takeda Oncology; University of Texas M. D. Anderson Cancer Center
- Class Amides; Antineoplastics; Antivirals; Chlorobenzenes; Organic boron compounds; Small molecules
- Mechanism of Action Apoptosis stimulants; Proteasome inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Multiple myeloma
- Phase III Amyloid light-chain amyloidosis
- Phase II Acute myeloid leukaemia; Amyloidosis; Follicular lymphoma; Graft-versus-host disease; Haematological malignancies; Mantle-cell lymphoma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Phase I/II HIV infections
- No development reported Lupus nephritis; Non-small cell lung cancer; Pancreatic cancer; Precursor cell lymphoblastic leukaemia-lymphoma
- Discontinued Bladder cancer; Solid tumours
Most Recent Events
- 03 Jul 2024 Takeda completes a phase II clinical trials in Amyloidosis in Belgium, Canada, China, Greece, Japan, South Korea, Poland, Singapore, Spain, Sweden, USA (PO) (EudraCT2016-001681-28) (NCT02924272)
- 03 Jul 2024 Takeda completes a phase II trial for Multiple myeloma in Belgium, Canada, China, Greece, Japan, South Korea, Poland, Singapore, Spain, Sweden, USA (PO) (EudraCT2016-001681-28) (NCT02924272)
- 03 Jul 2024 Takeda completes a phase-II clinical trials in Lymphoma in Belgium, Canada, China, Greece, Japan, South Korea, Poland, Singapore, Spain, Sweden, USA (PO) (EudraCT2016-001681-28) (NCT02924272)